Capuron et al. investigated depressive symptoms in patients with no history of mood disorder treated with IL-2 for metastatic cancer and found a positive correlation with depressive symptoms between baseline, when IL-2 based therapy was administered, and day 5 after administration (Capuron et al., 2001). This evidence concerns the gene IL2 and metastatic malignant neoplasm.